This Oral MS Drug Is Off to a Quick Start

Biogen Idec's (NASDAQ: BIIB  ) Tecfidera wasn't the first oral multiple sclerosis drug, but is sure has gotten off to a much faster start than Novartis' (NYSE: NVS  ) Gilenya, which was approved by the FDA in 2010 and Sanofi's (NYSE: SNY  ) Aubagio, which was approved in 2012.

In its third quarter on the market, Biogen registered nearly $400 million in sales, putting it well on its way to achieving blockbuster status. It's not hard to see Tecfidera catching more established injected drugs such as Teva Pharmaceuticals' Copaxone and Biogen Idec's own Avonex.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss why Biogen Idec got off to such a quick start where Novartis and Sanofi couldn't.

Looking for the next big thing
Every investor wants to get in on revolutionary ideas like Tecfidera before they hit it big. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure play" and then watch as it grows in explosive fashion with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 trillion industry. Click here to get the full story in this eye-opening report.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 17, 2014, at 12:42 AM, Pony wrote:

    Heres the issue with tecfidera: price. Tecfidera runs roughly 54,000$ per year. Im pretty sure its on a specialty tier of drugs under obamacare rules which means a hefty copay for MS patients. I know the copoay for copaxone(under my insurance,at least) is 2095$ per month. Which is also why i dont use it.

    I was diagnosed in 2008 with the relapsing remitting form of MS. I use an off label drug that has kept me walking these past 5 years, kept relapses short,few and as far between as any of the big drugs would have and its only cost me about 400$ for the year.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2877703, ~/Articles/ArticleHandler.aspx, 8/29/2014 10:20:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement